Advances in drug therapy for primary sclerosing cholangitis
- VernacularTitle:原发性硬化性胆管炎药物治疗进展
- Author:
Xia SHENG
1
;
Qingming JI
;
Xinyu LI
;
Lihong WANG
;
Junqi NIU
Author Information
- Keywords: Cholangitis,Sclerosing; Ursodeoxycholic Acid; Obecholic Acid; Drug Therapy
- From: Journal of Clinical Hepatology 2024;40(5):1032-1038
- CountryChina
- Language:Chinese
- Abstract: Primary sclerosing cholangitis(PSC)is a cholestatic disease characterized by chronic progressive bile duct inflammation and has a low incidence rate and poor prognosis in China.There is still no drug therapy that can change the course of PSC,and liver transplantation is the only effective treatment for PSC,with a 5-year survival rate of 85%after transplantation.Drug therapy for PSC is facing great challenges based on the current status of PSC.At present,drugs for the treatment of PSC are in the stage of clinical trials and have shown certain application prospect,among which ursodeoxycholic acid is the most widely studied and commonly used drug.In addition,there are many emerging drugs in the pipeline.This article summarizes the latest advances in drug therapy for PSC.
